The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics / targeted oral therapies and grow steadily over the next decade. The well-established TNF-α inhibitors (e.g., infliximab, adalimumab [AbbVie / Eisai’s Humira, biosimilars]), together with non-TNF biologics (i.e., Takeda’s Entyvio and Janssen’s Stelara), have transformed the treatment landscape for CD, especially for moderate to severe disease, despite these drugs’ efficacy limitations and safety risks. The impending entry of several new therapies offering more-convenient formulations and/or novel mechanisms of action (e.g., Galapagos / Gilead’s filgotinib, AbbVie’s risankizumab and upadacitinib, Janssen’s guselkumab) will further improve treatment and intensify market competition. Together with these trends, the continuing generic erosion of conventional agents and the availability of biosimilar TNF-α inhibitors will constrain CD therapy sales.
Geographies: United States, EU5, Japan.
Primary research: 24 country-specific interviews with thought-leading gastroenterologists supported by survey data collected for this and other DRG research.
Epidemiology: Diagnosed prevalence of Crohn’s disease by country, segmented by disease activity.
Forecast: Ten-year, annualized, drug-level sales and patient share of key Crohn’s disease therapies through 2029, segmented by brands/generics.
Emerging therapies: Phase III/PR: ~9 drugs; coverage of select preclinical, Phase I and Phase II products.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.